Skip to main content
SpringerLink
Log in

Carboplatin in malignant mesothelioma: A phase II study of the cancer and leukemia Group B

  • Original Articles
  • Carboplatin, Malignant Mesothelioma, Phase II Study
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

Carboplatin (400 mg/m2) was given at 28-day intervals to 41 patients with malignant mesothelioma. In all, 40 patients were eligible and evaluable for response. Partial responses were seen in 2 cases (5%); regression of evaluable disease, in 1 patient (2%); and stable disease, in 19 subjects (48%). A median of two doses of carboplatin per patient resulted in mild toxicity. Leukopenia (≤2,000 cells/μl) and thrombocytopenia (<100,000 cells/μl) were seen in only 6% and 20% of the patients, respectively. Median survival from study entry was estimated at 7.1 months, with a 1-year survival of 25%±7%. Carboplatin given at a dose of 400 mg/m2 at 28-day intervals shows minor activity against malignant mesothelioma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Aisner J, Sigman LM (1987) The role of chemotherapy in the treatment of malignant mesothelioma. In: Antman K, Aisner J (eds) Asbestos related malignancy. Grune & Stratton, Philadelphia, p 385

    Google Scholar 

  2. Alberts AS, Falkson G, Goedhals L, Vorobiof DA, Van Der Merwe CA (1988) Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers. J Clin Oncol 6: 527

    Google Scholar 

  3. Antman K, Shemin R, Ryan L, et al. (1988) Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965–1985. J Clin Oncol 6: 147

    Google Scholar 

  4. Antman KH, Li FP, Osteen R, et al. (1989) Mesothelioma. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Updates to Cancer: principles and practice of oncology, 3rd edn, vol 3 (1). J. B. Lippincott, Philadelphia

    Google Scholar 

  5. Atkinson NE, Brown BW (1985) Confidence limits for probability of response in multistage phase II clinical trials. Biometrics 41: 741

    Google Scholar 

  6. Bajorin D, Kelson D, Mintzer DM (1987) Phase II trial of mitomycin in malignant mesothelioma. Cancer Treat Rep 71: 857

    Google Scholar 

  7. Calvert AH, Newell DR, Gumbrell LA (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748

    Google Scholar 

  8. Cantwell BM, Franks CR, Harris AL (1986) A phase II study of the platinum analogues JM8 and JM9 in malignant pleural mesothelioma. Cancer Chemother Pharmacol 18: 286

    Google Scholar 

  9. Chahinian AP, Szrajer L, Malamud S, Schwartz PH, Holland JH (1985) Comparative activity of three platinum analogues against human malignant mesothelioma (HMM) xenografts in nude mice. Proc Am Assos Cancer Res 26: 261

    Google Scholar 

  10. Chahinian AP, Antman K, Aisner J (1987) Cisplatin with adriamycin or mitomycin for malignant mesothelioma: A randomized phase II trial. Proc Am Soc Clin Oncol 6: 183

    Google Scholar 

  11. Djerassi I, Kim JS, Kassarov L, Reggev A (1985) Response of mesothelioma to large doses of methotrexate with CF rescue (HDMTX-CF) used alone or with cis-platinum. Proc Am Soc Clin Oncol 4: 191

    Google Scholar 

  12. Egorin MJ, Van Echo DA, Tipping SJ, et al. (1984) Pharmacokinetics and dose reduction ofcis-diammine-(1,1-cyclobutanedicarboxylato) platinum in patients with impaired renal function. Cancer Res 44: 5432

    Google Scholar 

  13. Gore ME, Calvert AH, Smith IE (1987) High dose carboplatin in the treatment of lung cancer and mesothelioma: A phase I dose escalation study. Eur J Cancer Clin Oncol 23: 1391

    Google Scholar 

  14. Hsu S, Hsu S, Zhao X, Koo-Shan CS, Whang-Peng J (1988) Establishment of human mesothelioma cell lines (MS-1,-2) and production of a monoclonal antibody (Anti MS) with diagnostic and therapeutic potential. Cancer Res 48: 5228

    Google Scholar 

  15. Mbidde EK, Harland SJ, Calvert AH, Smith IE (1986) Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma. Cancer Chemother Pharmacol 18: 284

    Google Scholar 

  16. Mintzer DM, Kelson D, Frimmer D, Heeleen P, Gralla R, Ochoa M (1985) Phase II trial of high-dose cisplatin in patients with malignant mesothelioma. Cancer Treat Rep 69: 711

    Google Scholar 

  17. Popescu NC, Amsbaugh SC, Chahinian AP, Di Paola JS (1987) Non-random deletions of chromosome 3 (P14–21) in human malignant mesothelioma. Proc Am Assoc Cancer Res 28: 27

    Google Scholar 

  18. Raghavan D, Gianoutsos P, Bishop J, Lee J, Young I, Corte P, Bye P, McCaughan B (1989) Phase II trial of carboplatin in the management of malignant mesothelioma. J Clin Oncol 8: 151

    Google Scholar 

  19. Shea TC, Flaherty M, Elias A, et al. (1989) A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J Clin Oncol 7: 651

    Google Scholar 

  20. Vogelzang NJ, Schultz SM, Iannucci AM, Kennedy BJ (1984) Malignant mesothelioma: The University of Minnesota experience. Cancer 53: 377

    Google Scholar 

  21. Wolf KM, Piotrowski ZH, Engel JD, Bekeris LG, Palacios E, Fisher KA (1987) Malignant mesothelioma with occupational and environmental asbestos exposure in an Illinois Community Hospital. Arch Int Med 147: 2145

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Joint Section of Hematology/Oncology, University of Chicago, 5841 S. Maryland, Box 420, 60 637, Chicago, Illinois, USA

    Nicholas J. Vogelzang

  2. Harvard School of Public Health, Boston, Massachusetts

    Maria Goutsou

  3. Harvard Medical School, Brigham and Women's Hospital Surgical Pathology Division, Boston, Massachusetts

    Joseph M. Corson

  4. Departments of Community Medicine and Pathology, Mount Sinai School of Medicine, New York, New York

    Yasunosuke Suzuki

  5. SUNY-Health Science Center at Syracuse, New York

    Stephen Graziano

  6. University of Maryland Cancer Center, Baltimore, Maryland

    Joseph Aisner

  7. Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, North Carolina

    M. Robert Cooper

  8. Fiontier Science and Technology Research Foundation, Amherst, New York

    Kristine Mason Coughlin

  9. Department of Medicine and Cancer Center, University of California-San Diego, San Diego, California

    Mark R. Green

Authors
  1. Nicholas J. Vogelzang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria Goutsou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joseph M. Corson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yasunosuke Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Stephen Graziano
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Joseph Aisner
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Robert Cooper
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kristine Mason Coughlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Mark R. Green
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vogelzang, N.J., Goutsou, M., Corson, J.M. et al. Carboplatin in malignant mesothelioma: A phase II study of the cancer and leukemia Group B. Cancer Chemother. Pharmacol. 27, 239–242 (1990). https://doi.org/10.1007/BF00685720

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00685720

Keywords

Search

Navigation